Nintedanib is one of two oralantifibrotic agents approved for use in the treatment of IPF.Nintedanib is an intracellular tyrosine kinase inhibitor that targetsmultiple receptors such as vascular endothelial growth factor(VEGF), fibroblast growth factor (FGF), and platelet-derivedgrowth factor (PDGF) (1,2). Here, VEGFA is linked to idiopathic pulmonary fibrosis.